Literature DB >> 15028940

New estimates of herpes simplex virus type 2 seroprevalence in England: 'high' but stable seroprevalence over the last decade.

Marianne Morris-Cunnington1, David Brown, Jeanne Pimenta, Noah Jamie Robinson, Elizabeth Miller.   

Abstract

OBJECTIVES: There have been few recent population-based herpes simplex virus type 2 (HSV-2) seroprevalence studies in England, but reports from the United States have indicated a 30% rise in HSV-2 seroprevalence between 1976 and 1994. This study aimed to ascertain trends in HSV-2 infection in England between 1991 and 2000. STUDY
DESIGN: Anonymized serum residues collected through public health laboratories across England from individuals aged 16 to 64 years seeking health care through the National Health Service in 1991 (n = 2259) and 2000 (n = 3646) were tested for anti-HSV-2 IgG using the HerpeSelect 2 enzyme-linked immunosorbent assay IgG (Focus).
RESULTS: In 9 sites across England, the age- and sex-standardized HSV-2 seroprevalence was 9.7% (95% confidence interval, 8.4-11.0%). Data from 4 sites common to both study years indicated no change in HSV-2 seroprevalence between 1991 and 2000.
CONCLUSIONS: After adjustment for age, sex, and geographic location, there was no evidence of a change in seroprevalence between 1991 and 2000.

Entities:  

Mesh:

Year:  2004        PMID: 15028940     DOI: 10.1097/01.olq.0000118081.54177.95

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  2 in total

1.  Type specific seroprevalence of HSV-1 and HSV-2 in four geographical regions of Poland.

Authors:  J S Smith; M Rosinska; A Trzcinska; J M Pimenta; B Litwinska; J Siennicka
Journal:  Sex Transm Infect       Date:  2006-04       Impact factor: 3.519

2.  Seroprevalence of herpes simplex virus 1 and 2 in a population-based cohort in Japan.

Authors:  Yasufumi Doi; Toshiharu Ninomiya; Jun Hata; Koji Yonemoto; Yumihiro Tanizaki; Hisatomi Arima; Ying Liu; Mahbubur Rahman; Misuo Iida; Yutaka Kiyohara
Journal:  J Epidemiol       Date:  2009-03-06       Impact factor: 3.211

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.